Please login to the form below

Not currently logged in

Nabriva Therapeutics appoints new chief commercial officer

Francesco Maria Lavino joins to support commercialisation of its new antibiotic

Bacterial infections focussed Nabriva Therapeutics has appointed Francesco Maria Lavino as its chief commercial officer ahead of the group’s phase III clinical trial for lefamulin - a potential new treatment for community-acquired bacterial pneumonia.

Lavino joins the Austrian clinical-stage biopharma firm from Merck & Co (MSD), bringing nearly two decades of pharmaceutical sales and marketing experience with expertise in anti-infective medications.

He said: “Nabriva Therapeutics is poised to introduce what is potentially the first new class of antibiotics for systemic human use in nearly two decades.

“I am looking forward to working with the management team to address serious medical needs in lung, skin and potentially other types of infections.”

Prior to serving MSD as its acting vice president, global brand leader anti-infective portfolio, he was vice president, international marketing for the anti-infectives portfolio at Cubist Pharmaceuticals. He has also held roles at UCB Pharma and 3M in Italy.

Colin Broom, chief executive officer of Nabriva, said: “Francesco has the right experience and leadership qualities to build out a fully integrate commercial team and hospital field force in the US, and I am delighted to welcome him as part of our team.”

20th July 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...